RenovoRx (RNXT) announces the appointment of Mark Voll as the Company’s Chief Financial Officer, effective February 1, 2026. Voll brings more than three decades of financial leadership experience to RenovoRx. He has served as Chief Financial Officer for multiple publicly traded technology companies .
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx announces new clinical data on TAMP therapy platform
- RenovoRx initiated with a Buy at JonesResearch
- RenovoRx expands RenovoCath commercial adoption to nine cancer centers
- RenovoRx to announce new clinical data from Phase III TIGeR-PaC trial
- RenovoRx Receives Nasdaq Notice for Bid Price Noncompliance